Journal
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
Volume 6, Issue 9, Pages 1331-1346Publisher
JOHN WILEY & SONS LTD
DOI: 10.1177/2050640618799153
Keywords
Domperidone; metoclopramide; dosage; cardiovascular risk; sudden cardiac death; ventricular arrhythmia; QT prolongation; meta-analysis
Categories
Funding
- Neutec Ar-Ge San and Tic AS (Turkey)
Ask authors/readers for more resources
Background This meta-analysis aimed to assess the cardiac safety profile of domperidone treatment for the risk of cardiovascular (CV) event and QT prolongation. Methods Data from nine studies involving 101,155 patients were used for the analysis of CV event risk, while data from eight studies involving 390 patients were used for the analysis of QT prolongation risk. Results Meta-analysis findings suggested a significant increase in CV risk under domperidone as compared to no treatment for domperidone doses of >30 mg/day (OR: 3.14, 95% CI, 1.191 to 8.304, p = 0.021), no significant increase in QT prolongation event rates with domperidone (3.54%, 95% CI, 1.73% to 7.10%) and a significantly lower CV risk for domperidone than for metoclopramide (OR: 0.63, 95% CI, 0.58 to 0.70, p < 0.001). Conclusions The present meta-analysis indicates that domperidone treatment may not be associated with an overall CV event risk increase at doses <= 30 mg/day and does not result in QT prolongation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available